



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
30.08.2023 Bulletin 2023/35

(45) Date of publication and mention
of the grant of the patent:
26.07.2023 Bulletin 2023/30

(21) Application number: **12847165.3**

(22) Date of filing: **08.11.2012**

(51) International Patent Classification (IPC):
A61K 9/127 ^(2006.01) **A61K 9/00** ^(2006.01)

(52) Cooperative Patent Classification (CPC):
A61K 9/1271; A61K 9/0009; Y02A 50/30

(86) International application number:
PCT/US2012/064087

(87) International publication number:
WO 2013/070872 (16.05.2013 Gazette 2013/20)

(54) **METHODS AND COMPOSITIONS FOR X-RAY INDUCED RELEASE FROM PH SENSITIVE LIPOSOMES**

VERFAHREN UND ZUSAMMENSETZUNGEN ZUR RÖNTGENINDUZIERTEN FREISETZUNG
PH-EMPFLINDLICHER LIPOSOME

PROCÉDÉS ET COMPOSITIONS POUR LA LIBÉRATION INDUITE PAR RAYONS X DE LIPOSOMES
SENSIBLES AU PH

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **08.11.2011 US 201161556936 P**

(43) Date of publication of application:
17.09.2014 Bulletin 2014/38

(73) Proprietors:
• **The Board of Trustees of the University of
Arkansas**
Little Rock, AR 72207 (US)
• **BioVentures, LLC**
Little Rock, AR 72205-7199 (US)

(72) Inventors:
• **FOLOGEA, Daniel**
Boise, ID 83706 (US)
• **HENRY, Ralph**
Fayetteville, AR 72701 (US)
• **SALAMO, Greg**
Fayetteville, AR 72701 (US)

• **MAZUR, Yuriy**
Fayetteville, AR 72701 (US)
• **BORRELLI, Michael, J.**
Little Rock, AR 72205 (US)

(74) Representative: **Mewburn Ellis LLP**
Aurora Building
Counterslip
Bristol BS1 6BX (GB)

(56) References cited:
EP-A1- 0 312 212 EP-A1- 2 255 790
WO-A1-2010/129686 US-A- 5 770 222
US-A- 5 891 465 US-A1- 2006 099 141
US-A1- 2006 159 739 US-A1- 2011 105 995

• **CORY J. HITZMAN ET AL: "Development of a
respirable, sustained release microcarrier for
5-fluorouracil II: In vitro and in vivo optimization
of lipid coated nanoparticles", JOURNAL OF
PHARMACEUTICAL SCIENCES, vol. 95, no. 5, 1
May 2006 (2006-05-01), pages 1127-1143,
XP055183263, ISSN: 0022-3549, DOI:
10.1002/jps.20590**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- ROSENTHAL D J ET AL: "A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer", INVESTIGATIONAL NEW DRUGS, MARTINUS NIJHOFF PUBLISHERS, BOSTON, US, vol. 20, no. 3, 1 August 2002 (2002-08-01) , pages 343-349, XP002546528, ISSN: 0167-6997, DOI: 10.1023/A:1016201732368 [retrieved on 2004-11-02]